ArticleCase reports in oncology
Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review.Frontiers in immunology · 2020Pooled it
- Harnessing the Gut Microbiome in Cancer Immunotherapy: Mechanisms, Challenges, and Routes to Personalized Medicine-A Systematic Review.Technology in cancer research & treatmentPooled it
- Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.American journal of hematology · 2019Trial
- Hematological Toxicities in the Modern Era of Melanoma Therapy.Journal of clinical medicine · 2026Review
- Review
- Severe immunotherapy-related autoimmune hemolytic anemia induced by toripalimab in a patient with deficient mismatch repair colorectal cancer: a case report and literature review.Frontiers in medicine · 2025Article
- Immunotherapy-associated cardiovascular toxicities: insights from preclinical and clinical studies.Frontiers in oncology · 2024Review
- Immune Checkpoint Inhibitor-Induced Pure Red Cell Aplasia: A Review of 2 Cases in Metastatic Melanoma.The American journal of case reports · 2023Review
- Case report: A rare case of acute hemolysis in advanced rectal cancer after XELOX and nivolumab treatment: analysis of drug-dependent antibodies.Frontiers in medicine · 2023Article
- Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report.Translational lung cancer research · 2022Article
- Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report.JTO clinical and research reports · 2022Article
- Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report.Yeungnam University journal of medicine · 2021Article
- Effects of hydro-ethanolic extract of leaves of Maesa lanceolata (Mursinaceae) on acetic acid-induced ulcerative colitis in rats.Inflammopharmacology · 2021Article
- Bone marrow-derived mesenchymal stem cells inhibit CD8Clinical and experimental immunology · 2021Article
- Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors.Journal of the advanced practitioner in oncology · 2021Article
- Tolerization of recent thymic emigrants is required to prevent RBC-specific autoimmunity.Journal of autoimmunity · 2020Article
- Pembrolizumab-Induced Cold Agglutinin Disease.The American journal of case reports · 2020Article
- Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.Thoracic cancer · 2020Article
- Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.Nature reviews. Cardiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, immunotherapeutic drugs, including PD-1 inhibitors (nivolumab, pembrolizumab), PD-L1 inhibitors (atezolizumab, avelumab), and CTLA4 inhibitors (ipiliumumab), have emerged as important additions to the armamentarium against certain malignancies and have been incorporated into therapeutic protocols for first-, second-, or third-line agents for these metastatic cancers. Immune checkpoint inhibitor nivolumab is currently FDA approved for the treatment of patients with metastatic malignant melanoma [Redman et al.: BMC Med 2016;14: 20], metastatic non-small cell lung cancer [Guibert and Mazières: Expert Opin Biol Ther 2015;15: 1789-1797], metastatic renal cell cancer [Farolfi et al.: Expert Opin Drug Metab Toxicol 2016;12: 1089-1096], and relapsed or refractory classic Hodgkin's lymphoma [Villasboas and Ansell: Expert Rev Anticancer Ther 2016;16: 5-12]. Given the current and increasing indications for these drugs, it is essential for all physicians to become well versed with their common adverse effects and to be observant for other less documented clinical conditions that could be unmasked with the use of such medications. A definite association between autoimmune hemolytic anemia and the immune checkpoint inhibitor nivolumab has not been clearly documented, although a few cases have been reported recently [Kong et al.: Melanoma Res 2016;26: 202-204; Schwab et al.: Case Rep Oncol 2016;9: 373-378; Tardy et al.: Hematol Oncol 2016, DOI: 10.1002/hon.2338]. We report a case of fatal autoimmune hemolytic anemia refractory to steroids in a patient treated with nivolumab for metastatic lung cancer, and reflect on the other reported cases of autoimmune hemolytic anemia after the use of nivolumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.